# China NMPA Drug Inspection - Guilin Zhongnan (Bozhou) Pharmaceutical Technology Co., Ltd. - Bupleurum (Northern Bupleurum)

Source: https://www.globalkeysolutions.net/records/china_drug_inspection/guilin-zhongnan-bozhou-pharmaceutical-technology-co-ltd/b3127ff2-8508-4fd0-bf50-a370bb6e8d0c/
Source feed: China

> China NMPA drug inspection for Guilin Zhongnan (Bozhou) Pharmaceutical Technology Co., Ltd. published March 25, 2020. Drug: Bupleurum (Northern Bupleurum). 

---

## Details

- Record Type: CHINA_DRUG_INSPECTION
- Title: Drug Quality Bulletin of Guangxi Zhuang Autonomous Region Drug Administration (Issue 1, 2020)
- Company Name: Guilin Zhongnan (Bozhou) Pharmaceutical Technology Co., Ltd.
- Publication Date: 2020-03-25
- Drug Name: Bupleurum (Northern Bupleurum)
- Inspection Finding: [Characteristics]
- Action Taken: The Guangxi Zhuang Autonomous Region Drug Administration has organized relevant drug supervision and management departments to take necessary control measures against drugs that do not meet the standards and to handle them in accordance with the law.

Company: https://www.globalkeysolutions.net/companies/guilin-zhongnan-bozhou-pharmaceutical-technology-co-ltd/0622490e-15cc-4a99-869e-e99855ecefba/